Genprex, Inc.

(1) The Reverse Split will not have any impact in the number of shares of common stock we are authorized to issue under our Charter.

(2) Includes (i) warrants to purchase an aggregate of 1,981,079 shares of common stock with a weighted average exercise price of $10.05 per share, (ii) 80,000 shares of common stock underlying unvested restricted stock units, (iii) 283,573 shares of common stock issuable upon exercise of stock options, with a weighted average exercise price of $121.67 per share, (iv) 464,367 shares of common stock reserved for future issuance under the 2018 Plan (does not include 6,500,000 additional shares of common stock that may be available under the 2018 Plan if stockholders approve the Incentive Plan Proposal), and (v) 5,202 shares of common stock reserved for future issuance under the ESPP.

(3) The price per share indicated reflects solely the application of the applicable reverse split ratio to the closing price of the common stock on June 30, 2025.

After the effective date of the Reverse Split, our common stock would have a new committee on uniform securities identification procedures (CUSIP) number, a number used to identify our common stock.

Our common stock is currently registered under Section 12(b) of the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The proposed Reverse Split will not affect the registration of our common stock under the Exchange Act. Our common stock would continue to be reported on Nasdaq under the symbol “GNPX,” assuming that we are able to regain compliance with the Minimum Bid Price Requirement, although it is likely that Nasdaq would add the letter “D” to the end of the trading symbol for a period of twenty trading days after the effective date of the Reverse Split to indicate that the Reverse Split had occurred.